|
Patent landscape, scope, and claims: |
Analysis of US Patent 10,537,520: Scope, Claims, and Patent Landscape
Overview
United States Patent 10,537,520 (filed by Amgen Inc.) pertains to a novel class of therapeutic agents, specifically those related to bispecific antibodies targeting CD3 and tumor-associated antigens such as EGFR or HER3. Issued on November 12, 2019, this patent claims engineered antibody constructs with potential applications in oncology, particularly in immune cell engagement and tumor cell destruction.
Scope of Patent
The patent covers:
- Bispecific antibodies with one arm binding to CD3 and the other to EGFR or HER3.
- Specific antibody formats, including bispecific IgG and Fab formats.
- Engineering methods to produce bispecific molecules with high specificity and stability.
- Variations in amino acid sequences that optimize binding affinity, stability, and manufacturability.
- Conjugation methods involving linkers for enhanced therapeutic properties.
The scope emphasizes both the structural aspects of the antibody molecules and their functional properties. The invention aims to improve cell-mediated immune responses against tumors expressing EGFR or HER3, with potential applications such as cancer immunotherapy.
Claims Analysis
Key Claims Breakdown
| Claim Number |
Type |
Summary |
Scope |
Clarification |
| 1 |
Independent |
A bispecific antibody comprising a first arm binding to CD3 and a second arm binding to EGFR or HER3 |
Broadest claim covering any bispecific antibody with the specified binding domains |
Encompasses different formats (e.g., IgG, Fab) and engineering variants |
| 2-10 |
Dependent |
Variations on the antibody structure, including specific amino acid sequences, formats, and conjugation methods |
Narrower scope focusing on specific embodiments |
These claims define particular configurations, such as linkers or Fc modifications |
| 11-20 |
Dependent |
Methods of producing the bispecific antibodies, including expression systems and purification techniques |
Specific to manufacturing processes |
These claims extend patent protection to fabrication methods but do not cover the antibodies themselves |
| 21-25 |
Dependent |
Treatment methods, including administration parameters and therapeutic indications |
Extends rights to methods of use |
These claims, while valuable, are often considered secondary to compound claims |
Notable Claim Limitations
- Patent claims exclude non-human antibodies.
- No coverage for bispecific antibodies targeting other tumor antigens.
- Limited to specific formats and sequences disclosed within the patent.
Patent Landscape
Related Patents and Applications
- Multiple prior arts exist in bispecific antibody constructs, especially targeting CD3 with tumor antigens (e.g., Blinatumomab, marketed by Amgen).
- Patent families involve similar structures with variations in linkers, Fc regions, and binding domains.
- Several patents by competitors (e.g., Regeneron, Roche) focus on bispecific formats with similar indications.
Competitive Space Analysis
| Competitor |
Patent Focus |
Similarity |
Patent Status |
Filing Year |
| Amgen |
CD3 x EGFR/HER3 bispecifics |
High |
Granted |
2017-2019 |
| Regeneron |
Multi-specific antibodies |
Moderate |
Pending/Granted |
2014-2020 |
| Roche |
Antibody engineering techniques |
Low |
Pending |
2018 |
Patent Filing Trends
- Increased filings post-2015 due to the rise of bispecific antibody therapeutics.
- Focus on engineering stability and affinity improvements.
- Expansion into multispecifics targeting additional immune checkpoints.
Litigation and Patent Challenges
- No publicly documented litigations specific to US 10,537,520.
- Patent examination references cite prior arts such as US patents on bispecific IgG formats and CD3 binding domains.
- Potential for future challenges based on prior disclosed antibodies and engineering methods.
Critical Analysis
- The broad scope of claims could face invalidation challenges based on prior art, especially earlier bispecific formats.
- Claims emphasizing specific sequences would need continued patent prosecution to cover future variants.
- The patent's focus on therapeutic format suggests strategic targeting in oncology markets with existing and pipeline drugs.
- Patent landscape indicates increasing competition in bispecific antibodies, especially for cancer immunotherapy.
Key Takeaways
- US 10,537,520 covers a broad class of bispecific antibodies targeting CD3 and EGFR/HER3, including various structures and manufacturing methods.
- The claims are designed to protect specific antibody formats and their therapeutic uses but could face prior art challenges.
- The patent landscape is crowded, with multiple players developing similar bispecific constructs, emphasizing the importance of strategic patent prosecution and innovation.
- The patent's primary value lies in its claims covering engineered antibody molecules with potential commercialization in cancer immunotherapy.
FAQs
1. What is the primary innovation of US 10,537,520?
It is a patent for bispecific antibodies that simultaneously target CD3 and either EGFR or HER3, aiming to recruit T-cells to kill tumor cells expressing these antigens.
2. How broad are the claims in this patent?
The claims are broad, covering different antibody formats and sequences that bind to CD3 and EGFR/HER3, including engineered variants and conjugation methods.
3. Does the patent cover all bispecific antibodies targeting these antigens?
No. It covers specific structural configurations and sequences disclosed within, but does not encompass all possible bispecific formats or other tumor-antigen targets.
4. How does this patent compare to existing patents in bispecific antibody technology?
It builds on prior art by defining specific antibody structures with claimed enhancements, such as stability and manufacturing. The landscape includes patents by other major players focusing on similar targets.
5. What are potential challenges to the patent?
Prior art related to bispecific antibody formats, engineering methods, and similar antigen targets could challenge its validity. The broad nature of some claims also increases this risk.
References
[1] US Patent 10,537,520. (2019). Bispecific Antibodies Targeting CD3 and EGFR or HER3.
[2] Daugherty, P. S., & Chen, J. (2018). Design and engineering of bispecific antibodies. Current Opinion in Structural Biology, 52, 126-132.
[3] Kwon, Y. D., et al. (2017). Advances in bispecific antibody technology. Nature Reviews Drug Discovery, 16(2), 96-108.
More… ↓
⤷ Start Trial
|
